Kolexia
Jaccard Arnaud Médecine interne
Jaccard Arnaud
Médecine interne
Hôpital Dupuytren
Limoges, France
430 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Amylose à chaine légère d'immunoglobuline Amyloïdose Myélome multiple Lymphomes Lymphome T Paraprotéinémies Maladies rares Maladies du rein Syndrome POEMS

Collaborateurs

Voir plus
Bridoux Frank
Bridoux Frank
Hôpital La Miletrie, Poitiers, France
Roussel Murielle
Roussel Murielle
Hôpital Dupuytren, Limoges, France
Karlin Lionel
Karlin Lionel
Hôpital Lyon Sud, Pierre-Bénite, France
Arnulf Bertrand
Arnulf Bertrand
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Janssen
24 collaboration(s)
Dernière en 2023
Pfizer
9 collaboration(s)
Dernière en 2023
Oséus
4 collaboration(s)
Dernière en 2021
Takeda Pharmaceutical
4 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
LyMa101: Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
IsAMYP: A Phase 2, Open Label, Multicenter, Single-stage Study to Evaluate the Efficacy of Isatuximab Plus Pomalidomide and Dexamethasone (IPd), in Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
Essai Clinique (BMS)   05 mars 2024
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
Essai Clinique (Janssen)   27 février 2024
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Essai Clinique (Janssen)   27 février 2024
HEMATOVAC: Immunogénicité de la Vaccination Anti-pneumococcique Dans la leucémie aiguë et le Lymphome Chez l'Adulte
Essai Clinique (CHU Poitiers)   09 février 2024
Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study.
Clinical lymphoma, myeloma & leukemia   01 février 2024
AL amyloidosis
Youtube @ Filière de Santé Maladies Rares MaRIH   16 janvier 2024
[Congrès ASH 2023] Interview Arnaud JACCARD 🎙
Youtube @ Filière de Santé Maladies Rares MaRIH   10 janvier 2024
Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series.
Blood   14 décembre 2023
AGORA-1 /ALFA 2100 Study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML
Essai Clinique (Centre Antoine Lacassagne)   09 novembre 2023